Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moving forward: Herceptin in the adjuvant setting.

Elizabeth Tan-Chiu1, Martine Piccart

  • 1Cancer Research Network Inc., 350 NW 84th Avenue, Suite 305, Plantation, FL 33324, USA. elizabeth.tan-chiu@nsabp.org

Oncology
|November 8, 2002
PubMed
Summary

Four large trials are evaluating Herceptin (trastuzumab) for early-stage HER2-positive breast cancer. These studies aim to determine if this anti-HER2 antibody improves outcomes when given after initial treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026
Same author

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.

Frontiers in immunology·2026
Same author

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026
Same author

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal of the National Cancer Institute·2026

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • HER2 overexpression/amplification is linked to poor prognosis in breast cancer.
  • Herceptin (trastuzumab) is effective in metastatic HER2-positive breast cancer.
  • Earlier administration of Herceptin may enhance patient benefit.

Purpose of the Study:

  • To investigate the efficacy and safety of Herceptin in the adjuvant setting for HER2-positive primary breast cancer.
  • To compare different treatment regimens involving Herceptin in combination with standard therapies.
  • To identify the optimal treatment approach for early-stage HER2-positive breast cancer using Herceptin.

Main Methods:

  • Four large-scale, randomized clinical trials involving over 12,000 women with HER2-positive primary breast cancer.
  • Investigating Herceptin in combination with anthracycline/cyclophosphamide followed by paclitaxel (NSABP B31, Intergroup N9831).
  • Examining Herceptin with platinum salts/docetaxel (BCIRG 006) or as monotherapy for 1-2 years post-treatment (HERA Trial).

Main Results:

  • Ongoing trials are evaluating Herceptin's role in the adjuvant setting.
  • Data from these trials will inform optimal treatment strategies.
  • Herceptin has demonstrated a favorable safety profile and quality-of-life benefits.

Conclusions:

  • The rationale for using Herceptin in the adjuvant setting is supported by its efficacy in metastatic disease.
  • Large-scale trials are crucial for establishing the optimal use of Herceptin in early-stage breast cancer.
  • These comprehensive trials have the potential to define the best Herceptin-based adjuvant treatment approach.

Related Experiment Videos